knowledge -WSS

knowledge

author：knowledge 2025-09-30 01:19:31 - browse：56522

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Wegovy improves function in certain heart failure patients

WSS

Intellia plays down concerns on accidental germline transmission

ARCH Venture Partners is raising $3 billion for a life sciences fund

Biden administration opens offers in Medicare drug price negotiations

Vivek Ramaswamy made waves in the debate, much as in biotech

General Catalyst, Summa Health deal will turn on physician buy

Roche's accidental data boosts hopes for anti

focus

knowledge

explore

Novavax promises a turnaround & Lilly roils the obesity market

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How to make over

Drug repurposing or repositioning? The language matters

Vertigo drug brings hope for rare neuron disorder, Niemann

At least 13 dead in Texas as scorching temps continue

Quicker fix for pulse oximeters urged during FDA public meeting

New air purifier tech could be key to improving indoor air quality

Republicans love RFK Jr. What's that tell us about health in 2024?

knowledge

CDC says it’s too soon to assess risk posed by Covid subvariant

Vivek Ramaswamy made waves in the debate, much as in biotech

Do digital therapeutics have a future in medicine?

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

National associations that represent hospice owe an apology

Novo Nordisk to expand supply of Wegovy for U.S. patients

entertainment

hotspot

focus

explore